Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Calithera Biosciences Inc (CALA), BioFuel Energy Corp. (BIOF): Adage Capital Management and Third Point Are Bullish on These Companies

Phill Gross and Robert Atchinson’s Adage Capital Management and Dan Loeb’s Third Point are bullish on Calithera Biosciences Inc (NASDAQ:CALA) and BioFuel Energy Corp. (NASDAQ:BIOF), respectively. Adage Capital Management disclosed yesterday a new position, with 2.76 million shares of Common Stock, in Calithera Biosciences Inc (NASDAQ:CALA). In addition, Third Point made public its acquisition of 2.43 million shares of BioFuel Energy Corp. (NASDAQ:BIOF)’s Common Stock, for $5 per share.


Calithera Biosciences Inc (NASDAQ:CALA) is a $170.3 million market cap clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Adage Capital Management acknowledged ownership of 2.76 million shares of Common Stock, which account for almost 15.5% of the company’s shares outstanding. Adage started acquiring the company’s stock in October, when it went public, and paid prices ranging from the IPO price of $10.00 per share, to others as low as $6.80 per share (around mid-October).

Other major institutional investors that hold a stake larger than 10% in Calithera Biosciences Inc (NASDAQ:CALA) are Delphi Management Partners (more than 2.4 million shares), Morgenthaler Venture Partners (about 2.16 million shares), and Advanced Technology Ventures (2.11 million).

On the other hand, Dan Loeb’s Third Point disclosed the acquisition of 2.43 million shares of BioFuel Energy Corp. (NASDAQ:BIOF)’s Common Stock. Exercising in-the-money (or at-the-money) derivative securities, which expired on October 17 (the date on which the transaction took place), the fund paid $5 per share, and took its holdings to 3.48 million shares (of which Mr. Loeb can be deemed beneficial ownership, either directly or indirectly).

This stake makes of Third Point the largest institutional shareholder (amongst those we keep track of) in this $41.9 million market cap company engaged in the production and sale of ethanol and its co-products. Trailing Mr. Loeb’s fund are David Einhorn’s Greenlight Capital and Jim Simons’ Renaissance Technologies. Greenlight Capital acknowledged ownership of 2.21 million shares of BioFuel Energy Corp. (NASDAQ:BIOF) around mid-July (up from 1.42 million held by the end of the second quarter of the year), while Renaissance Technologies boosted its exposure to the company by 660% over the second quarter, and now owns 254,047 shares of Common Stock. Israel Englander’s Millennium Management can be also counted amongst the company’s bulls, with 20,642 shares.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!